Table 3.
Clinical and Biochemical Characteristics of Stages 0–2 and Stages 3–4 NAFLD
| Stages 0–2 NAFLD | Stages 3–4 NAFLD | P value | |
| Age (years) | 51.5 ± 13.4 | 52.8 ± 15.1 | 0.7564 |
| BMI (m/kg2) | 28.1 ± 4.9 | 30.2 ± 6.7 | 0.2133 |
| VFA (cm2) | 132.1 ± 63.7 | 135.7 ± 33.4 | 0.8716 |
| SFA (cm2) | 216.9 ± 95.3 | 256.8 ± 108.2 | 0.0626 |
| AST (U/ml) | 54.6 ± 41.0 | 58.1 ± 26.9 | 0.7526 |
| ALT (U/ml) | 80.3 ± 49.3 | 82.4 ± 59.5 | 0.8903 |
| FBS (mg/dl) | 122.9 ± 39.9 | 112.3 ± 17.8 | 0.3598 |
| IRI (ul/ml) | 13.0 ± 9.06 | 18.3 ± 9.10 | 0.0762 |
| HOMA-IR | 3.56 ± 2.59 | 5.16 ± 2.43 | 0.0677 |
| HDL cholesterol (mg/l) | 50.1 ± 12.5 | 47.8 ± 10.2 | 0.5277 |
| LDL cholesterol (mg/l) | 130.6 ± 33.3 | 129.8 ± 41.0 | 0.9430 |
| Albumin (mg/l) | 4.55 ± 0.27 | 4.23 ± 0.66 | 0.0170 |
| Platelet count (ng/ml) | 25.8 ± 6.6 | 20.0 ± 8.7 | 0.0134 |
| Hyaluronic acid (ng/dl) | 32.7 ± 27.8 | 72.4 ± 68.1 | 0.0090 |
| Type IV collagen 7s (ng/dl) | 4.65 ± 0.93 | 5.94 ± 1.53 | 0.0018 |
Data are expressed as means ± SD. VFA: visceral fat area, SFA: subcutaneous fat area, AST: aspartate aminotransferase, ALT: alanine aminotransferase, FBS: fasting blood sugar, IRI: immunoreactive insulin, HOMA-IR: homeostasis model assessment of insulin resistance.